Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $13.11 million. The enterprise value is -$8.35 million.
| Market Cap | 13.11M |
| Enterprise Value | -8.35M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 8.24 million shares outstanding. The number of shares has increased by 34.90% in one year.
| Current Share Class | 8.24M |
| Shares Outstanding | 8.24M |
| Shares Change (YoY) | +34.90% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 4.98% |
| Owned by Institutions (%) | 20.33% |
| Float | 6.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.50 |
| Forward PS | 28.34 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.36, with zero debt.
| Current Ratio | 11.36 |
| Quick Ratio | 10.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.86% and return on invested capital (ROIC) is -35.52%.
| Return on Equity (ROE) | -52.86% |
| Return on Assets (ROA) | -32.07% |
| Return on Invested Capital (ROIC) | -35.52% |
| Return on Capital Employed (ROCE) | -47.61% |
| Weighted Average Cost of Capital (WACC) | 7.01% |
| Revenue Per Employee | $267,497 |
| Profits Per Employee | -$666,483 |
| Employee Count | 14 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.98% in the last 52 weeks. The beta is 0.50, so Lipocine's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -44.98% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 46.26 |
| Average Volume (20 Days) | 237,549 |
Short Selling Information
The latest short interest is 351,433, so 4.26% of the outstanding shares have been sold short.
| Short Interest | 351,433 |
| Short Previous Month | 97,816 |
| Short % of Shares Out | 4.26% |
| Short % of Float | 5.39% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, Lipocine had revenue of $3.74 million and -$9.33 million in losses. Loss per share was -$1.29.
| Revenue | 3.74M |
| Gross Profit | 3.74M |
| Operating Income | -10.08M |
| Pretax Income | -9.33M |
| Net Income | -9.33M |
| EBITDA | -10.02M |
| EBIT | -10.08M |
| Loss Per Share | -$1.29 |
Balance Sheet
The company has $21.46 million in cash and no debt, with a net cash position of $21.46 million or $2.60 per share.
| Cash & Cash Equivalents | 21.46M |
| Total Debt | n/a |
| Net Cash | 21.46M |
| Net Cash Per Share | $2.60 |
| Equity (Book Value) | 21.16M |
| Book Value Per Share | 2.57 |
| Working Capital | 21.08M |
Cash Flow
| Operating Cash Flow | -11.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 58,925 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.19M |
| FCF Per Share | -$1.36 |
Margins
Gross margin is 100.00%, with operating and profit margins of -269.06% and -249.16%.
| Gross Margin | 100.00% |
| Operating Margin | -269.06% |
| Pretax Margin | -249.15% |
| Profit Margin | -249.16% |
| EBITDA Margin | -267.48% |
| EBIT Margin | -269.06% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.90% |
| Shareholder Yield | -34.90% |
| Earnings Yield | -81.31% |
| FCF Yield | -85.37% |
Analyst Forecast
The average price target for Lipocine is $5.00, which is 214.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.00 |
| Price Target Difference | 214.47% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -15.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |